Correctional Health · Overdose Prevention
Establishing a Safe Release Standard for Post-Incarceration Care
Shubham Bansal
The Overdose Risk Begins Immediately After Release
Opioid overdose is a leading cause of death in the period immediately after release from incarceration, driven by reduced opioid tolerance, interrupted treatment, unstable housing, and abrupt transitions in care [1,2].
In a landmark cohort study, the first two weeks after release from prison were associated with a markedly elevated risk of death from drug overdose compared with the general population [1].
More recent analyses that track both fatal and nonfatal events similarly show that overdose risk concentrates in the early post-release window and is closely tied to gaps in continuity of addiction care [2].
This pattern is not only a clinical problem affecting individuals. Instead, it reflects a failure in how prison-to-community transitions are designed.
Establishing a Safe Release Standard
One clear improvement is to establish a safe release standard for prison systems, defined as a minimum set of evidence-based steps that must occur before release for people at risk of opioid overdose.
In practice, this is analogous to a discharge bundle used in hospitals: a standardized pathway that ensures the highest-risk transition is supported by basic safeguards, rather than left to ad hoc decision-making.
A safe release standard does not require new pharmacology or novel clinical insights. It simply applies what is already known about overdose prevention and treatment continuity, and it makes those practices routine so that a person’s safety does not depend on the facility they leave, the county they return to, or whether a single staff member has time to coordinate reentry.
International guidance from the World Health Organization and the United Nations Office on Drugs and Crime emphasizes continuity of evidence-based treatment for drug dependence in custodial settings and linkage to care in the community [4].
In the United States, correctional health guidance increasingly frames medications for opioid use disorder (MOUD) and reentry planning as implementation problems rather than elective programming, highlighting service delivery models, staff training, and operational steps needed for consistent uptake [5]. This shift in framing matters because it positions safe release as a health services design problem, where the key question is not whether reentry support is desirable, but what minimum standard of transition should be considered safe.
International Models Demonstrate Feasibility
The United Kingdom offers a useful example of how system design can standardize outcomes when risk is concentrated around a predictable transition.
Scotland’s national take-home naloxone program is explicitly structured to reach people at high risk of opioid death, including those leaving prison, and has been evaluated using opioid-related deaths within weeks of prison release as a core outcome [7].
The significance of this model is not that the United States must adopt Scotland’s governance structure or commissioning arrangements, but that it demonstrates feasibility:
Naloxone-on-release can be treated as a routine system function, supported by written protocols and measurable targets, rather than as a discretionary add-on.
The Fragmented U.S. Reentry System
The baseline U.S. system stands in sharp contrast. Many jurisdictions still do not provide comprehensive MOUD access in custody, and reentry coordination varies widely across facilities and counties [3,5]. Even where treatment is initiated, continuity can break at the point of release because of administrative barriers, lack of identification, lapsed insurance, limited appointment availability, transportation constraints, and stigma in downstream settings.
The result is a fragmented pathway in which the highest-risk period is managed with the least reliable infrastructure.
A safe release standard would therefore treat release as a structured clinical handoff and would make a small number of steps non-negotiable for people at risk of opioid overdose. At a minimum, this includes:
Early identification of OUD and overdose risk, with a clear discharge plan that travels with the patient.
Initiation or continuation of MOUD during incarceration paired with a plan for uninterrupted dosing or rapid follow-up after release.
Provision of take-home naloxone at release with brief education that is realistic and non-stigmatizing.
Benefits activation and “warm” linkage to community care so that treatment and medications are actually accessible in the first days after release.
Basic release logistics designed around service availability, such as release timing that permits pharmacy access, clinic intake, and transportation.
The goal is not to create an idealized reentry program. It is to ensure that the system reliably delivers the minimum conditions for a safer transition.
Standardization Creates Accountability
Not only does standardization improve safety, but it also enables accountability and iterative improvement.
When safe release is framed as a defined bundle, systems can track a small number of indicators that directly measure implementation: the proportion of people released with an active MOUD plan and confirmed follow-up; the proportion released with naloxone in hand; the proportion with insurance active on day of release; and the frequency of documented medication gaps across the transition.
These measures convert a broad moral imperative into an operational agenda that can be audited and improved.
Evidence From Existing Programs
Experience with statewide correctional MOUD programs underscores why these components should be treated as standard rather than exceptional.
Implementation in Rhode Island’s unified jail and prison system, for example, has been associated with substantial reductions in post-incarceration deaths.
About the Author
Shubham Bansal
Shubham is a 2026 graduate of the University of Washington with a B.S. in Neuroscience and a minor in Anthropology. He is passionate about health systems design, translational neuroscience, and improving emergency response outcomes through addiction medicine and clinical innovation. His work spans computational immunology, overdose surveillance, and developing equitable, technology-driven emergency interventions for underserved populations. A U.S. Rhodes Scholar, he is currently pursuing a Master of Public Policy at the University of Oxford, with plans to integrate medicine, empirical research, and health policy to redesign public health delivery systems.


Leave a Reply